Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
ApexOnco Front Page
Recent articles
Chengdu Kanghong's KH815 enters human testing this month.
NVL-330 features among the latest crop of industry projects newly into human trials.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.